These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 6179595)

  • 1. Bleomycin hydrolase activity and cytotoxicity in human tumors.
    Lazo JS; Boland CJ; Schwartz PE
    Cancer Res; 1982 Oct; 42(10):4026-31. PubMed ID: 6179595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of bleomycin-resistant phenotypes of human cell sublines and circumvention of bleomycin resistance by liblomycin.
    Lazo JS; Braun ID; Labaree DC; Schisselbauer JC; Meandzija B; Newman RA; Kennedy KA
    Cancer Res; 1989 Jan; 49(1):185-90. PubMed ID: 2461797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bleomycin hydrolase activity in pulmonary cells.
    Lazo JS; Merrill WW; Pham ET; Lynch TJ; McCallister JD; Ingbar DH
    J Pharmacol Exp Ther; 1984 Dec; 231(3):583-8. PubMed ID: 6209387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substrate specificity of bleomycin hydrolase.
    Sebti SM; DeLeon JC; Ma LT; Hecht SM; Lazo JS
    Biochem Pharmacol; 1989 Jan; 38(1):141-7. PubMed ID: 2462878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Yeast cysteine proteinase gene ycp1 induces resistance to bleomycin in mammalian cells.
    Pei Z; Calmels TP; Creutz CE; Sebti SM
    Mol Pharmacol; 1995 Oct; 48(4):676-81. PubMed ID: 7476893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro selection and characterization of a bleomycin-resistant subline of B16 melanoma.
    Zuckerman JE; Raffin TA; Brown JM; Newman RA; Etiz BB; Sikic BI
    Cancer Res; 1986 Apr; 46(4 Pt 1):1748-53. PubMed ID: 2418953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lidocaine potentiation of bleomycin A2 cytotoxicity and DNA strand breakage in L1210 and human A-253 cells.
    Lazo JS; Braun ID; Meandzija B; Kennedy KA; Pham ET; Smaldone LF
    Cancer Res; 1985 May; 45(5):2103-9. PubMed ID: 2580616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic inactivation: a mechanism of human tumor resistance to bleomycin.
    Sebti SM; Jani JP; Mistry JS; Gorelik E; Lazo JS
    Cancer Res; 1991 Jan; 51(1):227-32. PubMed ID: 1703034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralization of bleomycin hydrolase by an epitope-specific antibody.
    Morris G; Mistry JS; Jani JP; Mignano JE; Sebti SM; Lazo JS
    Mol Pharmacol; 1992 Jul; 42(1):57-62. PubMed ID: 1378925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Chemosensitivity of adriamycin, mitomycin C, and bleomycin with in vitro colony assay].
    Miyamoto H; Inoue K; Arakawa M; Ogawa M
    Gan To Kagaku Ryoho; 1982 Nov; 9(11):1921-7. PubMed ID: 6191690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased glutathione level is not involved in enhanced bleomycin sensitivity in cisplatin-resistant 2780CP cells.
    Tanaka T; Kurokawa H; Matsuno K; Matsumoto S; Hayashida Y
    Anticancer Res; 2008; 28(5A):2663-8. PubMed ID: 19035292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and evaluation of fluoromycin: a novel fluorescence-labeled derivative of talisomycin S10b.
    Mistry JS; Jani JP; Morris G; Mujumdar RB; Reynolds IJ; Sebti SM; Lazo JS
    Cancer Res; 1992 Feb; 52(3):709-18. PubMed ID: 1370650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Sensitivity to bleomycin of human cultured tumor cells and analysis of related factors].
    Urade M; Sugi M; Shirasuna K; Sugiyama M; Miyazaki T
    Gan To Kagaku Ryoho; 1983 Nov; 10(11):2382-8. PubMed ID: 6195972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Up-regulation of antioxidant enzymes and coenzyme Q(10) in a human oral cancer cell line with acquired bleomycin resistance.
    Yen HC; Li SH; Majima HJ; Huang YH; Chen CP; Liu CC; Tu YC; Chen CW
    Free Radic Res; 2011 Jun; 45(6):707-16. PubMed ID: 21486114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Further characterization of bleomycin-resistant HeLa cells and analysis of resistance mechanism.
    Urade M; Sugi M; Matsuya T
    Jpn J Cancer Res; 1988 Apr; 79(4):491-500. PubMed ID: 2454906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary fate of [3H]bleomycin A2 in mice.
    Lazo JS; Pham ET
    J Pharmacol Exp Ther; 1984 Jan; 228(1):13-8. PubMed ID: 6198509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Separation of the protective enzyme bleomycin hydrolase from rabbit pulmonary aminopeptidases.
    Sebti SM; Lazo JS
    Biochemistry; 1987 Jan; 26(2):432-7. PubMed ID: 3103681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The mode of action of bleomycin-cell kinetic investigations (author's transl)].
    Ganzer U
    Laryngol Rhinol Otol (Stuttg); 1978 Mar; 57(3):177-86. PubMed ID: 77461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic structure and genetic mapping of the human neutral cysteine protease bleomycin hydrolase.
    Montoya SE; Ferrell RE; Lazo JS
    Cancer Res; 1997 Oct; 57(19):4191-5. PubMed ID: 9331073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Combined effect of bleomycin and SDB-ethylenediamine, a synthetic isoprenoid, on oral squamous carcinoma cell lines and transplantable nude mouse tumors].
    Takahashi Y; Urade M; Kishimoto H; Arimoto T; Yanagisawa T; Yoshioka W
    Gan To Kagaku Ryoho; 1995 Jun; 22(7):883-7. PubMed ID: 7540824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.